



The Effect of Melatonin on the Expression of H19, MALAT, HOTAIR, THRIL, and NOS Activity in *Leishmania major*-Infected Macrophages

Saina Karami¹, Reza Arjmand ^{1,*}, Jaseem Saki ¹, Dian Dayer ², Ali Jelowdar¹

¹ Department of Parasitology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

² Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Parasitology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: arjmand.reza@yahoo.com

Received 2023 December 5; Revised 2024 February 26; Accepted 2024 February 27.

Abstract

Background: *Leishmania* spp. protozoa cause *leishmaniasis* by infecting macrophages. Long non-coding RNAs (lncRNAs), such as H19, Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT), HOX Antisense Intergenic RNA (HOTAIR), and TNF and HNRNPL Related Immuno-regulatory lncRNA (THRIL), play a role in macrophage polarization and gene regulation. Additionally, leukocytes can synthesize and respond to melatonin, yet the regulatory role of melatonin in *Leishmania major*-infected macrophages is not well understood.

Objectives: This study aimed to assess the impact of melatonin on the expression of lncRNAs like H19, MALAT, HOTAIR, and THRIL, as well as on nitric oxide synthase (NOS) activity in *L. major*-infected macrophages.

Methods: *Leishmania major* promastigotes and U937 cell lines were cultured. Macrophages were infected with the promastigotes and subsequently treated with melatonin at concentrations of 3, 10, 30, and 100 nM for durations of 4, 24, and 48 hours. The expression levels of the lncRNAs and NOS activity were measured using quantitative Polymerase Chain Reaction (q-PCR) and spectrophotometry, respectively.

Results: Melatonin treatment (100 nM) significantly increased the expression of H19 compared to the control after 48 hours ($P = 0.002$). There was also a significant upregulation of MALAT and HOTAIR in macrophages treated with 3 nM melatonin compared to controls after 48 hours ($P = 0.02$ and $P = 0.003$, respectively). Additionally, THRIL expression significantly increased in the melatonin group (10 nM) compared to the control after 4 hours of treatment ($P = 0.003$). An increase in NOS activity was observed in the melatonin group (100 nM) compared to the control at 4 hours, 24 hours, and 48 hours ($P = 0.034$, $P = 0.011$, and $P = 0.014$, respectively).

Conclusions: The findings suggest that melatonin may enhance the expression of H19, THRIL, MALAT, and HOTAIR, as well as NOS activity in macrophages infected with *L. major*. The upregulation of these lncRNAs by melatonin could potentially improve the macrophages' ability to combat *L. major* infection.

Keywords: *Leishmania major*, Long ncRNAs, Melatonin, Macrophages, Nitric Oxide Synthase, Infections

1. Background

Leishmaniasis is an infectious disease prevalent in subtropical and tropical regions. This disease, which manifests various clinical characteristics, is caused by intracellular *Leishmania* spp. protozoans (1). It is estimated that annually, 20 000 - 30 000 deaths and 700 thousand to one million new cases occur (1-3). The disease appears in several forms (4); the most common is cutaneous *leishmaniasis* (CL), which poses a significant public health challenge, particularly in the Middle East (5). This infection is often overlooked

globally and predominantly affects individuals of lower economic status in both developed and developing countries (6). *leishmaniasis* is transmitted when female phlebotomus sandflies bite the skin of a host and deposit promastigotes, which are then phagocytosed by macrophages (7). Macrophages play a crucial role in controlling infections through the production of nitric oxide (NO) (8), which is synthesized by nitric oxide synthase 2 (NOS₂) from the substrate L-arginine (9). Numerous studies have demonstrated that immune responses to infectious pathogens are dependent on the expression of NOS₂ (8-10).

Additionally, long non-coding RNAs (lncRNAs) significantly influence the polarization of macrophages (11) and have been shown to enhance host immunity and responsiveness to various infections, including those induced by *Toxoplasma gondii* (12), *Schistosoma mansoni* (13), and *Trichomonas vaginalis* (14). Certain lncRNAs play crucial roles in activating macrophages and are key factors in immune responses to infections (15). H19, metastasis-associated lung adenocarcinoma transcript 1 (MALAT), HOX antisense intergenic RNA (HOTAIR), and TNF and HNRNPL Related Immunoregulatory Long Non-Coding RNA (THRIL) are lncRNAs that regulate gene expression in macrophages. They are instrumental in the differentiation, polarization, and activation of macrophages, as well as in the regulation of inflammatory responses (16, 17). Therefore, influencing these lncRNAs may enhance immune responses to infections.

A wide range of drugs is available for treating *Leishmaniasis*, including oral miltefosine, meglumine antimoniate, sodium stibogluconate, paromomycin, and amphotericin B (3, 18-20). However, issues such as extended half-life, toxicity, the development of drug resistance, and teratogenic effects make current therapy options inadequate (21-23). Other factors, including genetic and anthropometric characteristics, geographical area, and particularly immune status, can affect the efficacy of the medications used (24). These challenges have prompted researchers to develop new and innovative treatments to combat this infection. Additionally, ongoing efforts are being made annually to discover new inhibitors for this disease (25).

Melatonin, known as the "darkness hormone," is produced by the pineal gland at night, regulated by the central clock located in the suprachiasmatic nuclei of the hypothalamus. It is also synthesized by immune-competent cells and plays a role in monitoring infections and aiding recovery during acute defense responses (1). The role of melatonin in immune system activities and the regulation of inflammatory processes has been partially characterized; leukocytes are capable of synthesizing and responding to melatonin (26, 27). Previous studies have shown that melatonin is effective in decreasing susceptibility to bacterial infections (28), lethal endotoxemia (29), and several parasitic infections, including those induced by *S. mansoni* (30), *Plasmodium falciparum* and *P. chabaudi* (31), *Trypanosoma cruzi* (32), *Leishmania infantum* (33), and *L. amazonensis* (34). However, various studies have reported conflicting results regarding the regulatory effects of melatonin on NO production (27, 35, 36).

2. Objectives

To the best of our knowledge, no studies have investigated the effect of melatonin on the expression of certain lncRNAs such as H19, MALAT, HOTAIR, and THRIL, as well as NOS activity in *L. major*-infected macrophages. Therefore, the current study was designed to evaluate the regulatory effect of melatonin on the expression of these lncRNAs and NOS activity in *L. major*-infected macrophages.

3. Methods

3.1. Parasite Culture

Promastigotes of *L. major* (MRHO/IR/75/ER) were obtained from the Iranian Biological Resource Center (IBRC), Tehran, Iran. After confirmation via polymerase chain reaction (PCR) technique, the promastigotes were cultured in RPMI 1640 medium containing 100 µg/mL streptomycin, 100 U/mL penicillin, 2 mM L-glutamine, and 10% heat-inactivated Fetal Bovine Serum (FBS) (Gibco, USA). Cultures were maintained at 25°C for one week. In the stationary phase, the promastigotes were carefully transferred to fresh medium at a ratio of 1:4 (6).

3.2. Cell Culture

U937 cell lines, pro-monocytic/human histiocytic lymphoma cells, were acquired from the Pasteur Institute Cell Bank, Tehran, Iran. The cells were maintained in RPMI-1640 medium (Sigma-Aldrich Chemical Co, St. Louis, MO, USA) supplemented with 100 µg/mL streptomycin, 100 U/mL penicillin, 2 mM L-glutamine, and 10% heat-inactivated FBS (Gibco, USA), and incubated at 37°C in a 5% CO₂ atmosphere. The cells were stimulated with phorbol myristic acid (PMA) for three days to differentiate the monocytes into macrophages. Upon reaching approximately 80% confluency, the cells were passaged (6, 37).

3.3. In Vitro Macrophage Infection

Macrophage infection was carried out as previously described (6). Briefly, 1×10^6 cells/mL were seeded in a 6-well plate and incubated at 37°C for 24 hours. Subsequently, the macrophages were infected with promastigotes and maintained at 37°C for 4 hours. Non-phagocytosed promastigotes were removed by washing with Phosphate-Buffered Saline (PBS). After the PBS wash, the cells were treated with melatonin (98% purity, CAS no. 73-31-4, Sigma, USA) at concentrations of 3, 10, 30, and 100 nM for durations of 4, 24, and 48 hours. Melatonin was dissolved in Dimethyl sulfoxide (DMSO). This setup included a treated group (*Leishmania-*

infected macrophages treated with melatonin) and a control group (*Leishmania*-infected macrophages treated with DMSO). Finally, all cells were harvested using PBS containing 0.6 mM Ethylenediaminetetraacetic acid (EDTA) and stored at -80°C until further analysis. For confirmation of *Leishmania* infection, samples were smeared on slides, air-dried, fixed with methanol, and stained using the Giemsa method. All slides were carefully examined under a light microscope at a magnification of 1000x (38).

3.4. RNA Extraction, Reverse Transcription, and Quantitative PCR for lncRNAs

Initially, RNA samples were isolated using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The quantity and quality of the RNA samples were assessed using a NanoDrop Spectrophotometer (Thermo Scientific, USA) and gel electrophoresis. Table 1 lists the sequences of all primers used. Subsequently, cDNA synthesis of lncRNAs was performed using a cDNA synthesis kit (TaKaRa Bio, Tokyo, Japan) in a total volume of 20 μL . The synthesized cDNAs were immediately stored at -80°C for use in quantitative PCR (qPCR). The relative expression of lncRNAs H19, MALAT, HOTAIR, and THRIL was determined by qPCR using specific primers and Real Q Plus 2X Master Mix Green High ROX™ (Amplicon, Denmark). Reactions were conducted on a StepOne Plus™ instrument (ABI, USA) in a final volume of 20 μL , containing 1 μL of cDNA, 10 μM of each primer pair, 2X SYBR Green PCR Master Mix, and RNase-free water. The expression of lncRNAs was normalized to GAPDH expression as the internal control, and the delta-delta CT protocol was used to calculate the relative expression. All assays were performed in triplicate.

Table 1. Sequences of All Used Primers

Gene and Forward/Reverse Primers	Sequence (5' -> 3')	Product Length	Tm
MALAT1		179	
Forward	GGATTCAGGAAGGAGCGAG		59.89
Reverse	ACATATTGCCGACCTCACGG		60.18
H19		119	
Forward	CGGCCTTCCTGAACACCTTAG		60.68
Reverse	ATGTTGTTGGTTCTGGGAGC		60.25
HOTAIR		148	
Forward	TCTAACTGGCAGCACAGAGC		60.04
Reverse	CAAAGTCCCCTTTCAGCAGC		60.32
THRIL		146	
Forward	TCCAACTGAGACCTGGACC		58.94
Reverse	CTGGGATCAGCACTGTCTC		59.54

GAPDH		100
Forward	CAGCCTCAAGATCATCAGCAATG	60.0
Reverse	CATGAGTCTTCCACGATACCA	59.57

Abbreviation: Tm, melting temperature.

3.5. Quantification of NOS Activity

The nitrite (NO_2^-) content, indicative of NO production, was measured in the supernatant cultures of *Leishmania*-infected macrophages using the Griess reaction, as previously described (39). As a standard, the absorbance was measured at 540 nm following the incubation of 50 μL of the solution containing N-[naphthyl] ethylenediamine dihydrochloride (1 mg/mL), 5% phosphoric acid, and sulfanilamide (10 mg/mL) with 50 μL of the supernatant (39).

3.6. Statistical Analysis

The Shapiro-Wilk test was applied to assess the normality of data. Differences among groups were evaluated using one-way ANOVA with Tukey's HSD post hoc test for normally distributed variables and the Kruskal-Wallis H test for non-normally distributed variables. Data for normally distributed variables were presented as mean \pm standard error of the mean (SEM), and non-normally distributed data were presented as the median and interquartile range (IQR). All analyses were performed using IBM SPSS AMOS 21.0 (SPSS, Inc., Chicago, IL) and GraphPad Prism software, version 8 (GraphPad Software, CA). A P-value < 0.05 was considered statistically significant.

4. Results

Figure 1 displays *L. major*-infected macrophages stained using the Giemsa method. Furthermore, Figures 2 - 6 illustrate the effects of various concentrations of melatonin on the gene expression of H19, MALAT, HOTAIR, THRIL, and NOS activity in *L. major*-infected macrophages after treatments of 4, 24, and 48 hours, respectively. Our findings indicate that the expression of H19 increased approximately fourfold in the group treated with melatonin at a dose of 100 nM compared to the control group after 48 hours (Figure 2 P = 0.002). However, no significant differences were observed among other groups compared to the control group (P > 0.05). According to Figure 3C and 4C, a significant up-regulation in the expression of MALAT and HOTAIR was noted in *L. major*-infected macrophages treated with a concentration of 3 nM of melatonin compared to the control group after 48 hours of incubation (P = 0.02 and

P = 0.003, respectively). Nevertheless, there were no significant differences in the expression of MALAT and HOTAIR among other groups at different concentrations of melatonin (P > 0.05).



Figure 1. *Leishmania major*-infected macrophages stained with Giemsa method. The arrow indicates the location of the *Leishmania* protozoan.




Figure 2. Effect of different concentrations of melatonin on gene expression of H19 in *Leishmania major*-infected macrophages at 4 h (A), 24 h (B) and 48 h (C). The data are presented as mean \pm SEM.




Figure 3. Effect of different concentrations of melatonin on gene expression of MALAT in *Leishmania major*-infected macrophages at 4 h (A), 24 h (B) and 48 h (C). The data are presented as mean \pm SEM.




Figure 4. Effect of different concentrations of melatonin on gene expression of HOTAIR in *Leishmania major*-infected macrophages at 4 h (A), 24 h (B) and 48 h (C). The data are presented as mean \pm SEM.




Figure 5. Effect of different concentrations of melatonin on gene expression of HOTAIR in *Leishmania major*-infected macrophages at 4 h (A), 24 h (B) and 48 h (C). The data are presented as mean \pm SEM.




Figure 6. Effect of different concentrations of melatonin on nitric oxide synthase (NOS) activity in *Leishmania major*-infected macrophages at 4 h (A), 24 h (B) and 48 h (C). The data are presented as mean \pm SEM.

Regarding the expression of HOTAIR, a significant difference was observed in macrophages treated with a concentration of 10 nM of melatonin compared to the control group after 4 hours of treatment ($P = 0.003$). However, there were no significant differences among other groups compared to the control group at different concentrations of melatonin ($P > 0.05$). Additionally, as

shown in Figure 6A and 6C, an increase in NOS activity was detected in *L. major*-infected macrophages treated with melatonin at a concentration of 100 nM compared to the DMSO group after 4 hours, 24 hours, and 48 hours of treatment ($P = 0.034$, $P = 0.011$, and $P = 0.014$, respectively). Yet, no significant differences were observed among other groups compared to the control group at different concentrations of melatonin ($P > 0.05$).

5. Discussion

Leishmania protozoa are responsible for causing *Leishmaniasis*, which manifests a range of symptoms including visceral, mucocutaneous, cutaneous, and disseminated diseases (23). T helper-1 cells (Th1) secrete cytokines such as interferon-gamma (IFN- γ) and interleukin 12 (IL-12), which lead to immunity and resistance to *Leishmaniasis*. Conversely, Th2 cells mediate susceptibility to infection, exacerbating the disease through the production of IL-4, IL-5, and IL-10 (6). *Leishmania major* employs various strategies to evade detection by the immune system, forming a symbiotic relationship with its host to ensure its survival within macrophages (9). Meanwhile, melatonin stimulates antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase, and inhibits lipoxygenase (40). Additionally, leukocytes can synthesize and respond to melatonin (26). Indeed, melatonin has been shown to decrease susceptibility to bacterial (28) and parasitic infections (30). Given the immunomodulatory properties of melatonin and the key role of some lncRNAs in modulating the immune system, this study was designed to evaluate the regulatory effect of melatonin on the expression of lncRNAs and NOS activity in *L. major*-infected macrophages.

We observed an upregulation in the expression of MALAT and HOTAIR in *L. major*-infected macrophages treated with melatonin (3 nM) compared to the control group after 48 hours of treatment. HOTAIR plays a crucial role in activating NF- κ B (an inducible transcription factor involved in regulating inflammation) in macrophages and has been identified as a potential factor in immune responses to infections (15). It is known that *Leishmania* spp. parasites can inhibit NF- κ B activity in macrophages infected with promastigotes (39). Thus, the enhancing effect of melatonin on this specific lncRNA may improve the ability of macrophages to combat *L. major* infection. Conversely, it has been reported that MALAT1 interacts with the NF- κ B factor, suppressing its activity and potentially reducing the production of inflammatory

cytokines such as IL-6 and TNF- α . These contradictory findings suggest that the regulatory effects of these lncRNAs on the immune system are complex, and maintaining a balance between them (HOTAIR and MALAT1) is crucial (41).

Additionally, the results of this study show that the expression of H19 was significantly increased in the group treated with melatonin (100 nM) compared to the control group after 48 hours of incubation. However, no significant differences were observed among the other groups compared to the control group. To the best of our knowledge, this is the first study to evaluate specific lncRNAs in *L. major*-infected macrophages. H19, one of the earliest detected lncRNAs, primarily resides in the cytoplasm and is located on chromosome 11p15.5 in humans; it functions as a riboregulator or regulatory RNA (42). Despite this, findings regarding H19 are conflicting. This lncRNA plays key roles in the inflammatory process, fibrosis, and some cancers (43-45). Interestingly, H19 enhances M2 polarization (43) and has been shown to act as a molecular sponge for let-7 (46). Moreover, in 2018, Hashemi et al. (47) demonstrated that inhibition of let-7a in macrophages could represent a novel approach to treating *Leishmaniasis*.

As previously mentioned, macrophages control infections using NO produced by NOS₂ (9). In contrast, Arginase 1 (ARG1) is an immune-regulating enzyme that can reduce NO production by macrophages (48, 49). Th1-related cytokines such as IFN- γ , TNF, and GM-CSF activate phenotype 1 macrophages by increasing NOS₂ expression and decreasing ARG1 levels, thus controlling the proliferation of *Leishmania* spp. parasites (50, 51). In accordance with these findings, our study observed an increase in NOS activity in the melatonin group at a concentration of 100 nM compared to the DMSO/control group after 4 hours, 24 hours, and 48 hours of treatment. However, previous studies have shown that melatonin has varying regulatory effects, both increasing (35) and decreasing (34), on NO production (34, 35).

Furthermore, the expression of THRIL was significantly increased in the melatonin group (10 nM) compared to the control group after 4 hours of treatment. Notably, THRIL is involved in the regulatory expression of TNF- α in human monocytes (52, 53). TNF- α is known as a factor that activates macrophages to kill the *Leishmania* spp. parasite and plays an important role in protective immunity in cutaneous *Leishmaniasis* (54). Therefore, the increase of THRIL mediated by melatonin could potentially decrease this infection in *L. major*-infected macrophages. However,

further complementary studies are required in this area. The limitations of the present study include the lack of evaluation of other species related to *leishmaniasis*, and other lncRNAs and proteins associated with inflammation. Future research is necessary to confirm these findings and to understand their mechanisms. Our findings demonstrated that melatonin could increase the expression of H19 at a dose of 100 nM (after 48 hours), THRIL at a dose of 10 nM (after 4 hours), MALAT and HOTAIR at a dose of 3 nM (after 48 hours), as well as NOS activity at a dose of 100 nM (after 4, 24, and 48 hours) in *L. major*-infected macrophages. The changes occurred in a dose-time dependent manner. More complementary studies are needed in this regard.

5.1. Conclusions

To the best of our knowledge, no studies have investigated the effect of melatonin on the expression of lncRNAs such as H19, MALAT, HOTAIR, and THRIL, as well as NOS activity in *Leishmania major*-infected macrophages. Our findings indicate that melatonin could increase the expression of H19, THRIL, MALAT, and HOTAIR, as well as NOS activity in *Leishmania major*-infected macrophages. The enhancing effect of melatonin on these lncRNAs may improve the potential of macrophages to combat *L. major* infection. Future studies should consider evaluating the inhibition of lncRNAs and NOS mRNA expression levels through inhibitory transfection experiments to confirm the results of the current study.

Acknowledgements

This article is taken from the PhD thesis with the code OG-0047, so we would like to thank Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran for the funding support.

Footnotes

Authors' Contribution: SK and RA: Conceived and designed research as well as conducted experiments. JS and DD: Drafting the manuscript. AJ: Revised the manuscript. All authors read and approved the manuscript.

Conflict of Interests: The authors declared no conflicts of interest.

Data Availability: The datasets used and/or analyzed during the current study are available from the

corresponding author on reasonable request.

Ethical Approval: The protocol of the current study was reviewed and approved by the Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences (Approval No. [JR.AJUMS.MEDICINE.REC.1400.036](#)).

Funding/Support: The current study was funded by Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran with the code OG-0047.

References

- Fernandes JCR, Aoki JJ, Maia Acuna S, Zampieri RA, Markus RP, Floeter-Winter LM, et al. Melatonin and Leishmania amazonensis Infection Altered miR-294, miR-30e, and miR-302d Impacting on Tnf, Mcp-1, and Nos2 Expression. *Front Cell Infect Microbiol.* 2019;9:60. [PubMed ID: [30949455](#)]. [PubMed Central ID: [PMC6435487](#)]. <https://doi.org/10.3389/fcimb.2019.00060>.
- Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One.* 2012;7(5):e35671. [PubMed ID: [22693548](#)]. [PubMed Central ID: [PMC3365071](#)]. <https://doi.org/10.1371/journal.pone.0035671>.
- Singh P, Kumar M. Current treatment of visceral leishmaniasis (Kala-azar): an overview. *International Journal of Research in Medical Sciences.* 2014;2(3). <https://doi.org/10.5455/2320-6012.ijrms20140808>.
- Costa-da-Silva AC, Nascimento DO, Ferreira JRM, Guimaraes-Pinto K, Freire-de-Lima L, Morrot A, et al. Immune Responses in Leishmaniasis: An Overview. *Trop Med Infect Dis.* 2022;7(4). [PubMed ID: [35448829](#)]. [PubMed Central ID: [PMC9029249](#)]. <https://doi.org/10.3390/tropicalmed7040054>.
- Hepburn NC. Cutaneous leishmaniasis: current and future management. *Expert Rev Anti Infect Ther.* 2003;1(4):563-70. [PubMed ID: [15482153](#)]. <https://doi.org/10.1586/14787210.1.4.563>.
- Hamidi F, Mohammadi-Yeganeh S, Haji Molla Hoseini M, Seyyed Tabaei SJ, Taghipour N, Lasjerdi Z, et al. Inhibition of anti-inflammatory cytokines, IL-10 and TGF-beta, in Leishmania major infected macrophage by miRNAs: A new therapeutic modality against leishmaniasis. *Microb Pathog.* 2021;153:104777. [PubMed ID: [33592260](#)]. <https://doi.org/10.1016/j.micpath.2021.104777>.
- Borghi SM, Fattori V, Conchon-Costa I, Pinge-Filho P, Pavanelli WR, Verri WJ. Leishmania infection: painful or painless? *Parasitol Res.* 2017;116(2):465-75. [PubMed ID: [27933392](#)]. <https://doi.org/10.1007/s00436-016-5340-7>.
- Qadoumi M, Becker I, Donhauser N, Rollinghoff M, Bogdan C. Expression of inducible nitric oxide synthase in skin lesions of patients with american cutaneous leishmaniasis. *Infect Immun.* 2002;70(8):4638-42. [PubMed ID: [12117977](#)]. [PubMed Central ID: [PMC128200](#)]. <https://doi.org/10.1128/IAI.70.8.4638-4642.2002>.
- Cunningham AC. Parasitic adaptive mechanisms in infection by leishmania. *Exp Mol Pathol.* 2002;72(2):132-41. [PubMed ID: [11890722](#)]. <https://doi.org/10.1006/exmp.2002.2418>.
- Bogdan C, Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. *Int J Parasitol.* 1998;28(1):121-34. [PubMed ID: [9504340](#)]. [https://doi.org/10.1016/S0020-7519\(97\)00169-0](https://doi.org/10.1016/S0020-7519(97)00169-0).
- Reddy MA, Chen Z, Park JT, Wang M, Lanting L, Zhang Q, et al. Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. *Diabetes.* 2014;63(12):4249-61. [PubMed ID: [25008173](#)]. [PubMed Central ID: [PMC4238007](#)]. <https://doi.org/10.2337/db14-0298>.
- Menard KL, Haskins BE, Colombo AP, Denkers EY. Toxoplasma gondii Manipulates Expression of Host Long Noncoding RNA during Intracellular Infection. *Sci Rep.* 2018;8(1):15017. [PubMed ID: [30301916](#)]. [PubMed Central ID: [PMC6177471](#)]. <https://doi.org/10.1038/s41598-018-33274-5>.
- Vasconcelos EJR, daSilva LF, Pires DS, Lavezzo GM, Pereira ASA, Amaral MS, et al. The Schistosoma mansoni genome encodes thousands of long non-coding RNAs predicted to be functional at different parasite life-cycle stages. *Sci Rep.* 2017;7(1):10508. [PubMed ID: [28874839](#)]. [PubMed Central ID: [PMC5585378](#)]. <https://doi.org/10.1038/s41598-017-10853-6>.
- Woehle C, Kusdian G, Radine C, Graur D, Landan G, Gould SB. The parasite Trichomonas vaginalis expresses thousands of pseudogenes and long non-coding RNAs independently from functional neighbouring genes. *BMC Genomics.* 2014;15(1):906. [PubMed ID: [25326207](#)]. [PubMed Central ID: [PMC4223856](#)]. <https://doi.org/10.1186/1471-2164-15-906>.
- Obaid M, Udden SMN, Deb P, Shihabeddin N, Zaki MH, Mandal SS. LncRNA HOTAIR regulates lipopolysaccharide-induced cytokine expression and inflammatory response in macrophages. *Sci Rep.* 2018;8(1):15670. [PubMed ID: [30353135](#)]. [PubMed Central ID: [PMC6199307](#)]. <https://doi.org/10.1038/s41598-018-33722-2>.
- Triantaphyllopoulos KA. Long Non-Coding RNAs and Their "Discrete" Contribution to IBD and Johne's Disease-What Stands out in the Current Picture? A Comprehensive Review. *Int J Mol Sci.* 2023;24(17). [PubMed ID: [37686376](#)]. [PubMed Central ID: [PMC10487966](#)]. <https://doi.org/10.3390/ijms24173566>.
- Hosseini SA, Haddadi MH, Fathizadeh H, Nemati F, Aznaveh HM, Taraj F, et al. Long non-coding RNAs and gastric cancer: An update of potential biomarkers and therapeutic applications. *Biomed Pharmacother.* 2023;163:114407. [PubMed ID: [37100014](#)]. <https://doi.org/10.1016/j.biopha.2023.114407>.
- Registre C, Soares R, Rubio KTS, Santos ODH, Carneiro SP. A Systematic Review of Drug-Carrying Nanosystems Used in the Treatment of Leishmaniasis. *ACS Infect Dis.* 2023;9(3):423-49. [PubMed ID: [36795604](#)]. <https://doi.org/10.1021/acscinfecdis.2c00632>.
- Verdan M, Taveira I, Lima F, Abreu F, Nico D. Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022). *Expert Opin Ther Pat.* 2023;33(3):137-50. [PubMed ID: [37038719](#)]. <https://doi.org/10.1080/13543776.2023.2201431>.
- Kumar V, Madhu M, Murti K. An overview on leishmaniasis. *Viral, Parasitic, Bacterial, and Fungal Infections.* 2023. p. 389-406. <https://doi.org/10.1016/b978-0-323-85730-7.00055-2>.
- Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, Lopez-Velez R, Garcia-Hernandez R, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. *PLoS Negl Trop Dis.* 2017;11(12):e0006052. [PubMed ID: [29240765](#)]. [PubMed Central ID: [PMC5730103](#)]. <https://doi.org/10.1371/journal.pntd.0006052>.
- Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. *PLoS Negl Trop Dis.* 2017;11(5):e0005635. [PubMed ID: [28558062](#)]. [PubMed Central ID: [PMC5466346](#)]. <https://doi.org/10.1371/journal.pntd.0005635>.
- Zulfiqar B, Shelper TB, Avery VM. Leishmaniasis drug discovery: recent progress and challenges in assay development. *Drug Discov Today.* 2017;22(10):1516-31. [PubMed ID: [28647378](#)]. <https://doi.org/10.1016/j.drudis.2017.06.004>.
- Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et al. Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. *Clin Microbiol Rev.* 2018;31(4). [PubMed ID: [30158301](#)]. [PubMed Central ID: [PMC6148188](#)]. <https://doi.org/10.1128/CMR.00048-18>.

25. Vijayakumar S, Kant V, Das P. LeishInDB: A web-accessible resource for small molecule inhibitors against *Leishmania* sp. *Acta Trop.* 2019;**190**:375-9. [PubMed ID: 30552881]. <https://doi.org/10.1016/j.actatropica.2018.12.022>.
26. Elmahallawy EK, Luque JO, Aloweidi AS, Gutierrez-Fernandez J, Sampedro-Martinez A, Rodriguez-Granger J, et al. Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research. *Curr Med Chem.* 2015;**22**(33):3848-61. [PubMed ID: 26310920]. <https://doi.org/10.2174/0929867322666150827093730>.
27. Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. *Biochem Pharmacol.* 2010;**80**(12):1844-52. [PubMed ID: 20696138]. <https://doi.org/10.1016/j.bcp.2010.07.041>.
28. Rojas IG, Padgett DA, Sheridan JF, Marucha PT. Stress-induced susceptibility to bacterial infection during cutaneous wound healing. *Brain Behav Immun.* 2002;**16**(1):74-84. [PubMed ID: 11846442]. <https://doi.org/10.1006/brbi.2000.0619>.
29. Prendergast BJ, Hotchkiss AK, Bilbo SD, Kinsey SG, Nelson RJ. Photoperiodic adjustments in immune function protect Siberian hamsters from lethal endotoxemia. *J Biol Rhythms.* 2003;**18**(1):51-62. [PubMed ID: 12568244]. <https://doi.org/10.1177/0748730402239676>.
30. El-Sokkary GH, Omar HM, Hassanein AF, Cuzzocrea S, Reiter RJ. Melatonin reduces oxidative damage and increases survival of mice infected with *Schistosoma mansoni*. *Free Radic Biol Med.* 2002;**32**(4):319-32. [PubMed ID: 11841922]. [https://doi.org/10.1016/s0891-5849\(01\)00753-5](https://doi.org/10.1016/s0891-5849(01)00753-5).
31. Hotta CT, Gazarini ML, Beraldo FH, Varotti FP, Lopes C, Markus RP, et al. Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites. *Nat Cell Biol.* 2000;**2**(7):466-8. [PubMed ID: 10878815]. <https://doi.org/10.1038/35017112>.
32. Santello FH, Frare EO, Caetano LC, Alonso-Toldo MP, do Prado JJ. Melatonin enhances pro-inflammatory cytokine levels and protects against Chagas disease. *J Pineal Res.* 2008;**45**(1):79-85. [PubMed ID: 18284549]. <https://doi.org/10.1111/j.1600-079X.2008.00558.x>.
33. Elmahallawy EK, Jimenez-Aranda A, Martinez AS, Rodriguez-Granger J, Navarro-Alarcon M, Gutierrez-Fernandez J, et al. Activity of melatonin against *Leishmania infantum* promastigotes by mitochondrial dependent pathway. *Chem Biol Interact.* 2014;**220**:84-93. [PubMed ID: 24973643]. <https://doi.org/10.1016/j.cbi.2014.06.016>.
34. Laranjeira-Silva MF, Zampieri RA, Muxel SM, Floeter-Winter LM, Markus RP. Melatonin attenuates *Leishmania* (L.) amazonensis infection by modulating arginine metabolism. *J Pineal Res.* 2015;**59**(4):478-87. [PubMed ID: 26383232]. <https://doi.org/10.1111/jpi.12279>.
35. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin—a pleiotropic, orchestrating regulator molecule. *Prog Neurobiol.* 2011;**93**(3):350-84. [PubMed ID: 21193011]. <https://doi.org/10.1016/j.pneurobio.2010.12.004>.
36. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. *Curr Neuropharmacol.* 2010;**8**(3):228-42. [PubMed ID: 21358973]. [PubMed Central ID: PMC3001216]. <https://doi.org/10.2174/157015910792246155>.
37. Diotallevi A, De Santi M, Buffi G, Ceccarelli M, Vitale F, Galluzzi L, et al. *Leishmania* Infection Induces MicroRNA hsa-miR-346 in Human Cell Line-Derived Macrophages. *Front Microbiol.* 2018;**9**:1019. [PubMed ID: 29867904]. [PubMed Central ID: PMC5966562]. <https://doi.org/10.3389/fmicb.2018.01019>.
38. Khademvatan S, Neisi N, Maraghi S, Saki J. Diagnosis and identification of *Leishmania* spp. from Giemsa-stained slides, by real-time PCR and melting curve analysis in south-west of Iran. *Ann Trop Med Parasitol.* 2011;**105**(8):559-65. [PubMed ID: 22325815]. [PubMed Central ID: PMC4089809]. <https://doi.org/10.1179/2047773211Y.0000000014>.
39. Calegari-Silva TC, Pereira RM, De-Melo LD, Saraiva EM, Soares DC, Bellio M, et al. NF- κ B-mediated repression of iNOS expression in *Leishmania amazonensis* macrophage infection. *Immunol Lett.* 2009;**127**(1):19-26. [PubMed ID: 19712696]. <https://doi.org/10.1016/j.imlet.2009.08.009>.
40. Anisimov VN. Effects of exogenous melatonin—a review. *Toxicol Pathol.* 2003;**31**(6):589-603. [PubMed ID: 14585727]. <https://doi.org/10.1080/01926230390257885>.
41. Zhao G, Su Z, Song D, Mao Y, Mao X. The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF- κ B. *FEBS Lett.* 2016;**590**(17):2884-95. [PubMed ID: 27434861]. <https://doi.org/10.1002/1873-3468.12315>.
42. Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: Roles in tumorigenesis. *Biomed Pharmacother.* 2020;**123**:109774. [PubMed ID: 31855739]. <https://doi.org/10.1016/j.biopha.2019.109774>.
43. Ghafouri-Fard S, Abak A, Tavakkoli Avval S, Shoorei H, Taheri M, Samadian M. The impact of non-coding RNAs on macrophage polarization. *Biomed Pharmacother.* 2021;**142**:112112. [PubMed ID: 34449319]. <https://doi.org/10.1016/j.biopha.2021.112112>.
44. Xiao T, Zou Z, Xue J, Syed BM, Sun J, Dai X, et al. lncRNA H19-mediated M2 polarization of macrophages promotes myofibroblast differentiation in pulmonary fibrosis induced by arsenic exposure. *Environ Pollut.* 2021;**268**(Pt A):115810. [PubMed ID: 33162208]. <https://doi.org/10.1016/j.envpol.2020.115810>.
45. Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu P, et al. Macrophages-induced long noncoding RNA H19 up-regulation triggers myofibroblast differentiation in hepatocellular carcinoma. *Cancer Lett.* 2020;**469**:310-22. [PubMed ID: 31705929]. <https://doi.org/10.1016/j.canlet.2019.11.001>.
46. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. *Mol Cell.* 2013;**52**(1):101-12. [PubMed ID: 24055342]. [PubMed Central ID: PMC3843377]. <https://doi.org/10.1016/j.molcel.2013.08.027>.
47. Hashemi N, Sharifi M, Masjedi M, Tolouei S, Hashemi M, Mortazavidehkordi N, et al. Locked nucleic acid-anti-let-7a induces apoptosis and necrosis in macrophages infected with *Leishmania major*. *Microb Pathog.* 2018;**119**:193-9. [PubMed ID: 29655615]. <https://doi.org/10.1016/j.micpath.2018.03.057>.
48. Muxel SM, Laranjeira-Silva MF, Zampieri RA, Floeter-Winter LM. *Leishmania* (Leishmania) amazonensis induces macrophage miR-294 and miR-721 expression and modulates infection by targeting NOS2 and L-arginine metabolism. *Sci Rep.* 2017;**7**:44141. [PubMed ID: 28276497]. [PubMed Central ID: PMC5343489]. <https://doi.org/10.1038/srep44141>.
49. da Silva MF, Zampieri RA, Muxel SM, Beverley SM, Floeter-Winter LM. *Leishmania amazonensis* arginase compartmentalization in the glycosome is important for parasite infectivity. *PLoS One.* 2012;**7**(3):e34022. [PubMed ID: 22479507]. [PubMed Central ID: PMC3316525]. <https://doi.org/10.1371/journal.pone.0034022>.
50. Wang N, Liang H, Zen K. Molecular Mechanisms That Influence the Macrophage M1/M2 Polarization Balance. *Frontiers in Immunology.* 2014;**5**. <https://doi.org/10.3389/fimmu.2014.00614>.
51. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol.* 2004;**25**(12):677-86. [PubMed ID: 15530839]. <https://doi.org/10.1016/j.it.2004.09.015>.
52. Imamura K, Akimitsu N. Long Non-Coding RNAs Involved in Immune Responses. *Front Immunol.* 2014;**5**:573. [PubMed ID: 25431574]. [PubMed Central ID: PMC4230175]. <https://doi.org/10.3389/fimmu.2014.00573>.
53. Li Z, Chao TC, Chang KY, Lin N, Patil VS, Shimizu C, et al. The long noncoding RNA THRIL regulates TNF α expression through its interaction with hnRNPL. *Proc Natl Acad Sci U S A.* 2014;**111**(3):1002-7.

- [PubMed ID: [24371310](#)]. [PubMed Central ID: [PMC3903238](#)]. <https://doi.org/10.1073/pnas.1313768111>.
54. Liew FY, Parkinson C, Millott S, Severn A, Carrier M. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. *Immunology*. 1990;**69**(4):570.